Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review.
<h4>Background</h4>Immune checkpoint inhibitors (ICIs) for treatment of non-small cell lung cancer (NSCLC) have been rapidly evolving. ICIs are likely to be more effective but also lead to escalating healthcare costs.<h4>Objectives</h4>The aim of this study was to evaluate th...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2020-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0238536 |